EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Current State‐Of‐Play of the EU Advanced Therapy Medicinal Product ( ATMP ) Field, With an Emphasis on Belgian Human Cell and Tissue Products

Gilbert Verbeken iD, Lieke Convents, Nicolas Delmotte, Jean-Pierre Draye, Serge Jennes, Alain Vanderkelen, Griet Nijs, Philippe Lewalle, Etienne Baudoux iD, Olivier Cornu, Ineke Vanlaere, Anne Pierlot und 2 weitere

Wound Repair and Regeneration · 2025

DOI: 10.1111/wrr.70039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Wound Repair and Regeneration, 2025. Verfasst von Gilbert Verbeken und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussel, Belgium. Hauptthemen laut MEDLINE: Cell- and Tissue-Based Therapy, Tissue Engineering, Genetic Therapy, Wound Healing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The late 1980s saw the emergence of experimental therapies based on human cell and tissue products (HCTPs) within academic and hospital settings, several of them wound healing related. In 2008, the European Commission introduced the Regulation on advanced therapy medicinal products (ATMPs), defining many of these HCTPs as ATMPs, and more specifically as somatic cell therapy medicinal products (sCTMPs) or tissue‐engineered products (TEPs). In 2013, we predicted that the ATMP regulation would adversely impact Member States' health care systems and would threaten the sustainability of many HCTPs provided by public health institutions. To assess the current ATMP state of play and investigate whether these predictions ultimately came true, we consulted relevant scientific and trade literature and official competent authority reports and surveyed the former Belgian HCTP producers. We found that the ATMP Regulation produced 19 authorised ATMPs, with 16 of them (84.2%) belonging to the gene therapy medicinal product (GTMP) class and only 3 HCTPs (15.8%), 2 TEPs and 1 sCTMP. List prices varied according to the ATMP class, with public health insurances struggling to reimburse ATMPs, especially the exuberantly priced GTMPs. This led to marketing authorization withdrawals, and crowd funding approaches and lotteries to determine who would receive lifesaving treatments. A hospital exemption (HE) scheme was enacted to protect ATMPs not intended for commercial exploitation. Whilst limited financial resources generally hampered HE utilisation by public actors, stringent regulatory policies made it virtually impossible in Belgium, resulting in meaningful HCTPs no longer being available to surgeons and their patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell- and Tissue-Based TherapyTissue EngineeringGenetic TherapyWound HealingHumansBelgiumEuropean Union

Stichwörter der Autor:innen

advanced therapy medicinal productshospital exemptionhuman cell and tissue productskeratinocytestransplantation

Autor:innen und Institutionen

  • Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussel, Belgium.
  • Burn Wound Centre, Grand Hôpital de Charleroi, Gilly, Belgium.
  • Burn Wound Centre, Queen Astrid Military Hospital, Brussel, Belgium.
  • Centre for Gene Therapy and Regenerative Medicine, University Hospital Antwerp, Edegem, Belgium.
  • Haematology Department, HUB-Institute Jules Bordet, Brussels, Belgium.
  • Laboratory of Cell and Gene Therapy, CHU Liège, Liège, Belgium.

ORCID-Profile: Gilbert Verbeken, Etienne Baudoux

Zitieren

APA

Verbeken, G., Convents, L., Delmotte, N., Draye, J. P., Jennes, S., Vanderkelen, A., Nijs, G., Lewalle, P., Baudoux, E., Cornu, O., Vanlaere, I., Pierlot, A., Rose, T., & Pirnay, J. P. (2025). Current State‐Of‐Play of the EU Advanced Therapy Medicinal Product ( ATMP ) Field, With an Emphasis on Belgian Human Cell and Tissue Products. Wound Repair and Regeneration. https://doi.org/10.1111/wrr.70039

Vancouver

Verbeken G, Convents L, Delmotte N, Draye JP, Jennes S, Vanderkelen A, et al. Current State‐Of‐Play of the EU Advanced Therapy Medicinal Product ( ATMP ) Field, With an Emphasis on Belgian Human Cell and Tissue Products. Wound Repair and Regeneration. 2025. doi:10.1111/wrr.70039

BibTeX
@article{Verbeken2025,
  author = {Verbeken, Gilbert and Convents, Lieke and Delmotte, Nicolas and Draye, Jean-Pierre and Jennes, Serge and Vanderkelen, Alain and Nijs, Griet and Lewalle, Philippe and Baudoux, Etienne and Cornu, Olivier and Vanlaere, Ineke and Pierlot, Anne and Rose, Thomas and Pirnay, Jean-Paul},
  title = {Current State‐Of‐Play of the EU Advanced Therapy Medicinal Product ( ATMP ) Field, With an Emphasis on Belgian Human Cell and Tissue Products},
  journal = {Wound Repair and Regeneration},
  year = {2025},
  doi = {10.1111/wrr.70039}
}
Kostenlos starten →